Man Group’s Jyong Biotech MENS Stock Holding History

Man Group’s Portfolio MENS Stock Details MENS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,222	Closed	-$56.2K	–	2626
2025 Q4	$56.2K	Buy	+14,222	New	+$502K	﹤0.01%	2219

Other funds holding MENS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPIM

Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.32B AUM 51.82% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Man Group's MENS Position: Q1 2026 in Review

Man Group sold out of Jyong Biotech (MENS) in Q1 2026, closing a stake of 14,222 shares — an estimated $56.2K sold.

Man Group first reported a position in MENS in Q4 2025 and held it in 1 quarter. The position peaked at $56.2K in Q4 2025. 17 funds tracked by Wall St. Rank hold MENS as of Q1 2026.

Man Group reported no remaining Jyong Biotech position as of Q1 2026 after selling out during the quarter.
Man Group sold 14,222 Jyong Biotech shares in Q1 2026, an estimated $56.2K.
Man Group first reported a position in Jyong Biotech in Q4 2025 and held it in 1 quarter.
Man Group's Jyong Biotech position peaked at $56.2K in Q4 2025.
17 funds tracked by Wall St. Rank held Jyong Biotech as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.